Literature DB >> 16834738

The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia.

E Pollak1, H Mühlan, S VON Mackensen, M Bullinger.   

Abstract

As quality of life (QoL) research is increasingly focusing on children and adolescents with haemophilia, the need for both age-appropriate and disease-specific assessment tools becomes apparent. Therefore, a set of questionnaires measuring QoL in children and adolescents with haemophilia was simultaneously developed in six languages within the European Haemo-QoL project (Haemophilia, 8, 2002, 47; Haemophilia, 10, 2004, 17). For implementation in larger studies and for use in daily clinical routine, a both short and psychometrically robust version of the questionnaire is needed. Using from the Haemo-QoL field study complete data sets of 306 children and adolescents (4-16 years) and their parents, a multivariate approach of item selection was applied to construct an eight-item instrument, the Haemo-QoL Index. The instrument is applicable to different age groups and represents the core content as well as the multidimensional structure of the original long versions. According to preliminary analyses, the index's psychometric performance concerning reliability and convergent validity is good. Further validation of the instrument's performance on a new and independent sample is needed.

Entities:  

Mesh:

Year:  2006        PMID: 16834738     DOI: 10.1111/j.1365-2516.2006.01292.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

1.  Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.

Authors:  Beth Boulden Warren; Dianne Thornhill; Jill Stein; Michael Fadell; J David Ingram; Sharon Funk; Kristi L Norton; Heidi D Lane; Carolyn M Bennett; Amy Dunn; Michael Recht; Amy Shapiro; Marilyn J Manco-Johnson
Journal:  Blood Adv       Date:  2020-06-09

2.  A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Authors:  Guy Young; Ri Liesner; Tiffany Chang; Robert Sidonio; Johannes Oldenburg; Victor Jiménez-Yuste; Johnny Mahlangu; Rebecca Kruse-Jarres; Michael Wang; Marianne Uguen; Michelle Y Doral; Lilyan Y Wright; Christophe Schmitt; Gallia G Levy; Midori Shima; Maria Elisa Mancuso
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

3.  The social burden and quality of life of patients with haemophilia in Italy.

Authors:  Yllka Kodra; Marianna Cavazza; Arrigo Schieppati; Marta De Santis; Patrizio Armeni; Romano Arcieri; Gabriele Calizzani; Giovanni Fattore; Lamberto Manzoli; Lorenzo Mantovani; Domenica Taruscio
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 4.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

5.  Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study.

Authors:  Christine L Kempton; Michael Wang; Michael Recht; Anne Neff; Amy D Shapiro; Amit Soni; Roshni Kulkarni; Tyler W Buckner; Katharine Batt; Neeraj N Iyer; David L Cooper
Journal:  Patient Prefer Adherence       Date:  2017-09-19       Impact factor: 2.711

6.  Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Authors:  Johnny Mahlangu; Johannes Oldenburg; Michael U Callaghan; Midori Shima; Maria Elisa Mancuso; Peter Trask; Michael Recht; Claudia Garcia; Renchi Yang; Michaela Lehle; Harrison Macharia; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres; Sylvia von Mackensen
Journal:  Haemophilia       Date:  2019-04-24       Impact factor: 4.287

7.  Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study.

Authors:  Angela L Forsyth; Michelle Witkop; Angela Lambing; Cesar Garrido; Spencer Dunn; David L Cooper; Diane J Nugent
Journal:  Patient Prefer Adherence       Date:  2015-10-29       Impact factor: 2.711

8.  Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Authors:  Noémie Resseguier; Natacha Rosso-Delsemme; Any Beltran Anzola; Karine Baumstarck; Vanessa Milien; Laurent Ardillon; Sophie Bayart; Claire Berger; Marie-Anne Bertrand; Christine Biron-Andreani; Annie Borel-Derlon; Sabine Castet; Pierre Chamouni; Ségolène Claeyssens Donadel; Emmanuelle De Raucourt; Dominique Desprez; Céline Falaise; Birgit Frotscher; Valérie Gay; Jenny Goudemand; Yves Gruel; Benoît Guillet; Annie Harroche; Abel Hassoun; Yoann Huguenin; Thierry Lambert; Aurélien Lebreton; Anne Lienhart; Michèle Martin; Sandrine Meunier; Fabrice Monpoux; Guillaume Mourey; Claude Negrier; Philippe Nguyen; Placide Nyombe; Caroline Oudot; Brigitte Pan-Petesch; Benoît Polack; Anne Rafowicz; Antoine Rauch; Delphine Rivaud; Pascale Schneider; Alexandra Spiegel; Cecile Stoven; Brigitte Tardy; Marc Trossaërt; Jean-Baptiste Valentin; Stéphane Vanderbecken; Fabienne Volot; Annelise Voyer-Ebrard; Bénédicte Wibaut; Tanguy Leroy; Thomas Sannie; Hervé Chambost; Pascal Auquier
Journal:  BMJ Open       Date:  2018-07-25       Impact factor: 2.692

Review 9.  Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.

Authors:  Sandra Le Quellec
Journal:  Drug Des Devel Ther       Date:  2020-02-03       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.